Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Formulation Development, Optimization by Box-Behnken Design, and In Vitro Characterization of Gefitinib Phospholipid Complex Based Nanoemulsion Drug Delivery System
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been authorized for the treatment of non-small lung cancer; however, its applications are not restricted. Instead, it ...